{"id":1006066,"date":"2026-09-27T17:03:06","date_gmt":"2026-09-27T21:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/"},"modified":"2026-09-27T17:03:06","modified_gmt":"2026-09-27T21:03:06","slug":"mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/","title":{"rendered":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026"},"content":{"rendered":"

<\/p>\n

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026<\/b><\/p>\n

FOSTER CITY, Calif.–(BUSINESS WIRE<\/a>)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV), along with 48-week data from the Phase 2b portion of the study.<\/p>\n

Conference Call Details:<\/strong><\/p>\n

US\/Toll-Free: +1 833 461 5787
International: +1 585 542 9983
Access Code: 979912911<\/p>\n

You may also access the call via webcast by visiting the Investors<\/a> section of Mirum\u2019s corporate website. The archived webcast will be available for replay.<\/p>\n

About Mirum Pharmaceuticals<\/strong><\/p>\n

Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company\u2019s commercial portfolio includes LIVMARLI\u00ae (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis(PFIC),ATEBRIOZ\u2122 (zilurgisertib) tablets for fibrodysplasia ossificans progressiva (FOP), CHOLBAM\u00ae (cholic acid) for bile-acid synthesis disorders and CTEXLI\u00ae (chenodiol) for cerebrotendinous xanthomatosis (CTX).<\/p>\n

Mirum\u2019s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).<\/p>\n

Mirum\u2019s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com<\/a> and follow Mirum on Facebook<\/a>, LinkedIn<\/a>, Instagram<\/a> and X<\/a>.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260927892676\/en\/<\/a><\/span><\/p>\n

Investor Contact:<\/b>
Andrew McKibben
ir@mirumpharma.com<\/a><\/p>\n

Media Contact:<\/b>
Meredith Kiernan
media@mirumpharma.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV), along with 48-week data from the Phase 2b portion of the study. Conference Call Details: US\/Toll-Free: +1 833 461 5787International: +1 585 542 9983Access Code: 979912911 You may also access the call via webcast by visiting the Investors section of Mirum\u2019s corporate website. … <\/p>\n

Continue reading “Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006066","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV), along with 48-week data from the Phase 2b portion of the study. Conference Call Details: US\/Toll-Free: +1 833 461 5787International: +1 585 542 9983Access Code: 979912911 You may also access the call via webcast by visiting the Investors section of Mirum\u2019s corporate website. … Continue reading "Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-27T21:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026\",\"datePublished\":\"2026-09-27T21:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/\"},\"wordCount\":379,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/\",\"name\":\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-09-27T21:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/","og_locale":"en_US","og_type":"article","og_title":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Market Newsdesk","og_description":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, September 28, 2026 at 8:30 a.m. ET\/5:30 a.m. PT to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV), along with 48-week data from the Phase 2b portion of the study. Conference Call Details: US\/Toll-Free: +1 833 461 5787International: +1 585 542 9983Access Code: 979912911 You may also access the call via webcast by visiting the Investors section of Mirum\u2019s corporate website. … Continue reading \"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-27T21:03:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026","datePublished":"2026-09-27T21:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/"},"wordCount":379,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/","name":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-09-27T21:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260927892676r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mirum-pharmaceuticals-to-host-investor-call-to-share-topline-results-from-the-phase-3-azure-1-study-of-brelovitug-in-chronic-hepatitis-delta-on-september-28-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006066"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006066\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}